

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jenscare Scientific Co., Ltd.**  
**寧波健世科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 9877)**

**ANNOUNCEMENT IN RELATION TO  
GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE  
FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION**

Reference is made to the announcement of Jenscare Scientific Co., Ltd. (the “**Company**”) dated March 11, 2024 in relation to the issuance of the Filing Notice by the CSRC in respect of the Company’s H Share Full Circulation application (the “**Announcement**”). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcement.

**LISTING APPROVAL BY THE STOCK EXCHANGE**

The board of directors (the “**Directors**”) of the Company is pleased to announce that the Company has applied to the Listing Committee of the Stock Exchange for the approval (the “**Listing Approval**”) of the listing of and the permission to deal in 178,715,577 H shares (the “**Converted H Shares**”) of the Company (the “**Unlisted Shares**”) to be converted under the Conversion and Listing. The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on March 15, 2024.

**Shareholding Structure**

The Conversion and Listing will involve a total of 23 participating holders of 178,715,577 Unlisted Shares and the number of the Converted H Shares held by such participating holders represents approximately 42.84% of the total issued shares of the Company.

Set out below is the percentage holding in the Company in relation to the participating shareholders of the Unlisted Shares upon completion of the Conversion and Listing.

<b>Name of the participating shareholders (the “Participating Shareholders”) of the Unlisted Shares</b>	<b>Number of Unlisted Shares converted to H shares</b>	<b>Approximate percentage of total issued shares of the Company upon completion of the Conversion and Listing (%)</b>
Lv Shiwen	5,888,376	1.41
Ningbo Sangdi Investment Management L.P. (Limited Partnership) (寧波桑迪投資管理合夥企業(有限合夥))	20,107,386	4.82
Ningbo Mukang Venture Capital Partnership (Limited Partnership) (寧波沐康創業投資合夥企業(有限合夥))	3,883,626	0.93
Ningbo Kefeng Investment Management L.P. (Limited Partnership) (寧波鈞豐投資管理合夥企業(有限合夥))	8,448,804	2.03
Hainan Maidu Enterprise Management L.P. (Limited Partnership) (海南脈迪企業管理合夥企業(有限合夥))	26,520,141	6.36
Hainan Huahui Investment L.P. (Limited Partnership) (海南華暉投資合夥企業(有限合夥))	14,716,059	3.53
Hainan Hualing Investment L.P. (Limited Partnership) (海南華翎投資合夥企業(有限合夥))	16,363,620	3.92
Shanghai Shidi Industrial Development Co., Ltd. (上海仕地實業發展有限公司)	13,778,856	3.30
Ningbo Linfeng Biotechnology Co., Ltd. (寧波麟豐生物科技有限公司)	13,720,590	3.29
AUT-VII HK Holdings Limited	10,875,000	2.61
Zhuhai Yuheng Equity Investment L.P. (Limited Partnership) (珠海嶼恒股權投資合夥企業(有限合夥))	9,309,060	2.23
Qiushi Xingde (Tianjin) Investment Center (Limited Partnership) (秋實興德(天津)投資中心(有限合夥))	2,160,000	0.52
Janecox Investment IV HK Limited	1,575,000	0.38
Suzhou Chenzhide Investment L.P. (Limited Partnership) (蘇州辰知德投資合夥企業(有限合夥))	5,672,160	1.36
Suzhou Bilinxing Venture Capital Partnership (Limited Partnership) (蘇州比鄰星創業投資合夥企業(有限合夥))	748,080	0.18
Shanghai Jinpu Medical and Health Equity Investment Partnership (Limited Partnership) (上海金浦醫療健康股權投資合夥企業 (有限合夥))	2,431,260	0.58
Beijing People’s Renbao Health Industry Investment Fund (Limited Partnership) (北京人保健康養老產業投資基金(有限合夥))	1,199,988	0.29
Shanghai Changxiang Medical Technology Center (Limited Partnership) (上海暢想醫療科技中心(有限合夥))	1,309,122	0.31

Name of the participating shareholders (the “Participating Shareholders”) of the Unlisted Shares	Number of Unlisted Shares converted to H shares	Approximate percentage of total issued shares of the Company upon completion of the Conversion and Listing (%)
China Life Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) (國壽成達(上海)健康產業股權投資中心(有限合夥))	8,509,176	2.04
CICC Pucheng Investment Co., Ltd. (中金浦成投資有限公司)	1,701,882	0.41
Tianjin Fanchuan Management Consulting Partnership (Limited Partnership) (天津梵川管理諮詢合夥企業(有限合夥))	5,994,144	1.44
Tianjin Fanshi Management Consulting Partnership (Limited Partnership) (天津梵石管理諮詢合夥企業(有限合夥))	1,990,170	0.48
Duckling Fund, L.P.	1,813,077	0.43
<b>Total</b>	<b>178,715,577</b>	<b>42.84</b>

*Note:* The percentages have been rounded up to two decimal places. Accordingly, the total percentage may not equal to the apparent total percentage.

Upon completion of the Conversion and Listing, the share capital structure of the Company will be as follows:

Class of shares	As at the date of this announcement		Upon completion of the Conversion and Listing	
	<i>Number of shares</i>	<i>Approximate percentage %</i>	<i>Number of shares</i>	<i>Approximate percentage %</i>
H shares	131,590,632	31.54	310,306,209	74.38%
Unlisted shares	285,576,658	68.46	106,861,081	25.62%
<b>Total</b>	<b>417,167,290</b>	<b>100.00</b>	<b>417,167,290</b>	<b>100.00</b>

*Note:* The percentages have been rounded up to two decimal places. Accordingly, the total percentage may not equal to the apparent total percentage.

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in compliance with the requirements under the Listing Rules and applicable laws, as and when appropriate.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.**

By order of the Board  
**Jenscare Scientific Co., Ltd.**  
**Mr. LV Shiwen**  
*Chairman and Executive Director*

Hong Kong, March 15, 2024

*The English names of the PRC entities, departments, facilities, certificates, titles, laws, regulations and the like are translations of their Chinese names and are included for identification purposes only. If there is any inconsistency, the Chinese name prevails.*

*As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.*